Inhibition of separated forms of cyclic nucleotide phosphodiesterase from pig coronary arteries by 1,3-disubstituted and 1,3,8-trisubstituted xanthines

Abstract

A series of xanthines with varied substituents in the 1, 3, and 8 positions were prepared in an attempt to understand the structure--activity relationship for alkylxanthines as inhibitors of two different forms of cyclic nucleotide phosphodiesterase. Polar substituents on the 1 or 3 position of the xanthine reduced the potency of the xanthines to inhibit both the calmodulin-sensitive and the "cyclic AMP specific" forms of phosphodiesterase. Polar substituents on the 8 position of the xanthine, other than a carboxylic acid, increased the potency to inhibit the calmodulin-sensitive form of phosphodiesterase, if they were capable of donating electrons to the xanthine nucleus. On the other hand, any substituent in the 8 position larger than H reduced the potency of the xanthines to inhibit the cyclic AMP specific form of phosphodiesterase. Topographical maps of the active sites of the two forms of phosphodiesterase are presented in summary.

Caffeine analogs: biomedical impact

“…However, a recent report indicated that IBMX has no effect on PDE8 [69]. Extensive pioneering studies on alkylxanthines by Wells and colleagues [70,71] led to xanthines with some selectivity, namely 3-isobutyl-1-isoamylxanthine (IIX, see Fig. 6) toward PDE4 and 8-methoxymethylIBMX (8-MeOCH 2 -IBMX, see Fig.…”

Phosphodiesterase: overview of protein structures, potential therapeutic applications and recent progress in drug development

“…Obviously, altering the rate of cyclic nucleotide formation or degradation will change the activation state of these pathways [11]. By the late 1970s and early 1980s it became clear that kinetically distinct PDEs could indeed be inhibited selectively by a variety of small organic molecules [12][13][14][15]. As there are big therapeutic markets and unmet medical needs for the diseases related to PDE proteins, research and development on PDE inhibitors is growing rapidly.…”

Phosphodiesterase 5 (PDE 5) inhibitors for the treatment of male erectile disorder: Attaining selectivity versus PDE6

“…For several decades, xanthines 45,91 were known to be weak and nonselective inhibitors of PDEs, as exemplified by a prototypical compound, 1-methyl-3-isobutylxanthine (IBMX, Fig. 17) and its analogs.…”